Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3861045 | The Journal of Urology | 2014 | 11 Pages |
Abstract
Intermediate risk disease is a heterogeneous category, and there is a paucity of independent studies comparing therapies and outcomes in subgroups of intermediate risk patients. The IBCG has proposed a management algorithm that considers tumor characteristics, timing and frequency of recurrence, and previous treatment. Subgroup analyses of intermediate risk subjects in pivotal EORTC trials and meta-analyses will be important to validate the proposed algorithm and support clear evidence-based recommendations for subgroups of intermediate risk patients.
Keywords
MMCICUDNCCN®AUANMIBCSWOGintravesicalTURBTEORTCMitomycin CPDDCISBCGNBIBacillus Calmette-GuérinEAUAdjuvantAmerican Urological AssociationEuropean Association of UrologyTransurethral resection of bladder tumorPhotodynamic diagnosisnarrow band imagingRiskintermediate riskEuropean Organisation for Research and Treatment of CancerNonmuscle invasive bladder cancerUrinary bladder neoplasmsNational Comprehensive Cancer NetworkChemotherapyMycobacterium bovisAdministrationCarcinoma in situSouthwest Oncology Group
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Ashish M. Kamat, J. Alfred Witjes, Maurizio Brausi, Mark Soloway, Donald Lamm, Raj Persad, Roger Buckley, Andreas Böhle, Marc Colombel, Joan Palou,